Cite
HARVARD Citation
Vermeire, S. et al. (2022). Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet gastroenterology and hepatology. pp. 28-37. [Online].